$9.20
+0.02 (+0.22%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RNAC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 4 with posted results
Held by 9 tracked-famous managers (Squarepoint Ops LLC, AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, +4 more) · FINRA short interest 14.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersNCT07089121Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Descartes-08 | Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis | 50 | Dec 2027 | ≤ 499 d | 2026-07-27 |
| Descartes-08 in Autoantibody MyositisNCT07391605Major improvement of 2016 ACR/EULAR Total Improvement scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Descartes-08 · Other: Placebo | Antisynthetase Syndrome | 60 | Nov 2027 | ≤ 468 d | 2026-08-17 |
| Descartes-08 for Patients With Systemic Lupus ErythematosusNCT06038474Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Descartes-08 | Systemic Lupus Erythematosus (SLE) | 6 | 2026-12-01 | in 104 d | 2026-03-27 |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247Myasthenia Gravis Activities of Daily Living (MG-ADL)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: Decartes-08 · Other: Placebo Drug | Myasthaenia Gravis | 100 | 2026-11-30 | in 103 d | 2026-03-24 |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)NCT04146051Proportion of patients with MG Composite improvement of ≥5 points.Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Descartes-08 | Myasthenia Gravis, Generalized | 30 | 2026-01-05actual | — | 2026-08-14 |
| Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaNCT06304636Determine the safety of Descartes-15 in patients with relapsed/refractory multiple myeloma (R/R MM)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Phase 1 enrollment completed. Further clinical development terminated | Drug: Descartes-15 | Refractory Multiple Myeloma, Relapsed Multiple Myeloma | 4 | 2025-04-14actual | — | 2025-11-24 |
| Descartes-25 in Relapsed/Refractory Multiple MyelomaNCT05113342Maximum Tolerated DoseNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Phase 1 enrollment completed. Further clinical development terminated. | Drug: Descartes-25 | Multiple Myeloma, Relapse Multiple Myeloma | 9 | 2023-05-09actual | — | 2024-11-12 |
| Study of Descartes-30 in Acute Respiratory Distress SyndromeNCT04524962results2024-10-29To Assess the Safety of Descartes-30 in Patients With Moderate-to-severe ARDS.Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Phase 1 enrollment completed. Further clinical development terminated | Biological: Descartes 30 | Acute Respiratory Distress Syndrome, Covid19 | 12 | 2022-09-09actual | — | 2024-10-29 |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyNCT04816526results2024-10-08Rate of Stringent Complete ResponseOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Biological: Descartes 08 | Myeloma Multiple | 13 | 2022-08-04actual | — | 2024-10-08 |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyNCT04436029results2024-12-03Rate of Stringent Complete ResponseOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Descartes 11 | Multiple Myeloma | 5 | 2022-02-18actual | — | 2024-12-03 |
| Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaNCT03994705results2025-04-25Number of Participants With Treatment-Related Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Phase 1 enrollment completed. Further clinical development terminated. | Biological: Descartes-11 · Drug: Fludarabine, Cyclophosphamide | Multiple Myeloma | 20 | 2021-05-27actual | — | 2025-05-15 |
| Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaNCT03448978Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Phase 1 enrollment completed. Further clinical development terminated | Biological: Descartes-08 · Drug: Fludarabine, Cyclophosphamide | Multiple Myeloma | 32 | 2021-04-19actual | — | 2024-07-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19